Valuation: Processa Pharmaceuticals, Inc.

Market Cap 5.77M 5.24M 4.84M 4.37M 8.25M 541M 8.54M 58.2M 23.06M 290M 21.63M 21.18M 920M P/E 2024
-0.23x
P/E 2025 -0.28x
Enterprise Value 228K 207K 191K 173K 326K 21.42M 338K 2.3M 912K 11.49M 856K 838K 36.41M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
84.83%
Yield 2024 *
-
Yield 2025 -
1 day-7.53%
1 week-11.79%
Current month-8.99%
1 month+1.78%
3 months-29.22%
6 months-41.89%
Current year-40.28%
1 week 1.64
Extreme 1.64
1.91
1 month 1.59
Extreme 1.59
2.1
Current year 1.04
Extreme 1.041
3.8
1 year 1.04
Extreme 1.041
8.88
3 years 1.04
Extreme 1.041
435
5 years 1.04
Extreme 1.041
3,099.9
10 years 1.04
Extreme 1.041
125,195.11
Manager TitleAgeSince
Chief Executive Officer 52 2023-08-07
Chief Administrative Officer 61 2017-10-03
Investor Relations Contact 60 2011-03-28
Director TitleAgeSince
Chairman 73 2011-03-28
Director/Board Member 56 2020-02-12
Director/Board Member 68 2022-07-10
Date Insider Type Main position Quantity % Market Cap. Importance
8/8/26 Exercice

Chief Executive Officer

3,200 0.1156%
7/26/26 Other

Chief Financial Officer

11,883 0.4293%
7/26/26 Other

Chief Executive Officer

9,384 0.3390%
Change 5-day change 1-year change 3-year change Capi.($)
-7.53%-11.79%-77.07%-99.17% 5.77M
-1.29%-3.91%+51.98%+69.06% 65.56B
-2.96%-1.43%+7.50%+88.33% 60.41B
-0.95%+0.67%+23.36%+87.44% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
+0.23%+2.14%+14.85%+46.22% 36.7B
-3.15%-16.63%+146.30%+685.27% 36.09B
-2.14%-3.13%+75.60%+56.47% 32.9B
+1.42%+5.84%-36.40%+402.78% 26.96B
Average -1.77%-2.65%+23.85%+148.31% 40B
Weighted average by Cap. -1.27%-1.58%+34.45%+149.82%

Financials

2024 2025
Net sales - -
Net income -11.85M -10.77M -9.95M -8.98M -16.96M -1.11B -17.55M -120M -47.4M -597M -44.47M -43.53M -1.89B -13.56M -12.32M -11.39M -10.28M -19.41M -1.27B -20.09M -137M -54.25M -683M -50.9M -49.82M -2.16B
Net Debt -1.12M -1.02M -938K -848K -1.6M -105M -1.66M -11.28M -4.47M -56.32M -4.19M -4.11M -178M -5.54M -5.03M -4.65M -4.2M -7.92M -520M -8.2M -55.89M -22.15M -279M -20.78M -20.34M -884M
Projected Income Statement - Annual - Processa Pharmaceuticals, Inc.
Logo Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. Its oncology pipeline consists of NGC-Cap and NGC-Iri (also identified as PCS6422 and PCS11T, respectively) and two non-oncology drugs (PCS12852 and PCS499). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan. PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes. Its pipelines also include VT-7208, a Bruton's tyrosine kinase inhibitor therapy for immune-mediated diseases.
Employees
12
Date Price Change Volume
26-11-16 US$1.720 -7.53% 34,710
26-11-13 US$1.860 +1.09% 18,737
26-11-12 US$1.840 -1.60% 16,353
26-11-11 US$1.870 0.00% 45,000
26-11-10 US$1.870 -4.10% 17,371
  1. Stock Market
  2. Stocks
  3. PCSA Stock